Gsk trying balance east and west hansoh deal success showed chinas potential

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

GSK has been operating a strategy of “balancing the West and the East” since the Big Pharma’s eyes were opened to the potential of licensing drugs from China two years ago, according to an executive.